Skip to content


  • Erratum
  • Open Access

Erratum to: TRIzol treatment of secretory phase endometrium allows combined proteomic and mRNA microarray analysis of the same sample in women with and without endometriosis

  • Amelie Fassbender,
  • Peter Simsa,
  • Cleophas M Kyama,
  • Etienne Waelkens,
  • Attila Mihalyi,
  • Christel Meuleman,
  • Olivier Gevaert,
  • Raf Van de Plas,
  • Bart de Moor and
  • Thomas M D'Hooghe1, 2, 3, 4Email author
Reproductive Biology and Endocrinology20119:44

Received: 29 March 2011

Accepted: 6 April 2011

Published: 6 April 2011

The original article was published in Reproductive Biology and Endocrinology 2010 8:123

Since publication of our article [1], we have realised that we did not include the full data in Table 1 and missed the word (TOF) in the result/discussion section. We have provided here the adapted sentence and another version of the table, including all the information intended.
Table 1

The representative molecular weights of the proteins identified in the mRNA Microarray study [Thirteen] [2]


Mass in Da

Osteoglycin (OGN/4969)


Interleukin-6 signal transducer (IL6ST/3572)

isoform 1 103,537

isoform 2 37,499

Cytochrome P450, Family 2, Subfamily J, polypeptide 2 (CYP2J2/1573)


Carboxypeptidase E (CPE/1363)


Fibronectin 1 (FN1/2335)

different isoforms


   1. 262,607


   2. 71,943


   3. 259,198


   4. 222,944


   5. 243,316


   6. 240,477


   7. 268,894


   8. 252,793


   9. 246,670


   10. 239,608


   11. 262,388


   12. 221,274


   13. 249,304


   14. 249,384


   15. 272,302

Synuclein, gamma (SNCG/6623)


BAI1-associated protein 2 (BAIAP2/10458)

different isoforms


   1. 60,868


   2. 59,014


   3. 56,626


   4. 57,359


   5. 57,445


   6. 57,430

Protocadherin 17 (PCDH17/27253)

different isoforms


   1. 126,229


   2. 96,570

Protein tyrosine phosphatase, receptor type, R (PTPRR/5801)

Alpha 73,834 Da

Gamma 46,581Da

Delta 51,046Da


"Therefore, we plan to repeat this study in a larger sample size including well defined endometrial samples obtained during menstrual, follicular and secretory phase, to validate the reproducibility of SELDI-TOF MS technology in these samples and to identify the protein peaks observed after proteomic analysis, which are expensive and labour intense requiring High-performance liquid chromatography or high-pressure liquid chromatography (HPLC) and matrix assisted laser desorption ionization Time-of-Flight-Mass Spectrometry (MALDI-TOF/TOF MS)."


Authors’ Affiliations

Department of Obstetrics & Gynaecology, Leuven University Fertility Centre,University Hospital Gasthuisberg, Leuven, Belgium
Division of Reproductive Health and Biology, Institute of Primate Research, Karen, Nairobi, Kenya
Biochemistry Section, Department of Molecular Cell Biology, Campus Gasthuisberg, Leuven, Belgium
Department of Electrical Engineering, ESAT-SCD, K.U.Leuven,Kasteelpark-Arenberg 10, Heverlee, Belgium


  1. Fassbender Amelie, Simsa Peter, Kyama Cleophas, Waelkens Etienne, Mihalyi Attila, Meuleman Christel, Gevaert Olivier, Van de Plas Raf, de Moor Bart, D'Hooghe Thomas: TRIzol treatment of secretory phase endometrium allows combined proteomic and mRNA microarray analysis of the same sample in women with and without endometriosis. Reproductive Biology and Endocrinology. 2010, 8: 123-10.1186/1477-7827-8-123.PubMed CentralView ArticleGoogle Scholar
  2. Sherwin JR, Sharkey AM, Mihalyi A, Simsa P, Catalano RD, D'Hooghe TM: Global gene analysis of late secretory phase, eutopic endometrium does not provide the basis for a minimally invasive test of endometriosis. Hum Reprod. 2008, 23 (5): 1063-1068. 10.1093/humrep/den078.View ArticleGoogle Scholar


© Fassbender et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.